Decoy Therapeutics Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Decoy Therapeutics Inc. (DCOY) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $462.79 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $462.79K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $437.33K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $455.19K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $484.20K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $462.79K 10-K · filed 2026-03-31 | |
| 2024-12-31 | $437.33K 10-K · filed 2026-03-31 | |
| 2023-12-31 | $455.19K 10-K · filed 2025-03-21 | |
| 2022-12-31 | $484.20K 10-K · filed 2024-03-22 | |
| 2021-12-31 | $50.65K 10-K · filed 2023-03-27 | |
| 2020-12-31 | $28.05K 10-K · filed 2022-03-25 | |
| 2019-12-31 | $70.11K 10-K · filed 2021-03-18 | $70.00K 10-K · filed 2020-03-23 |
| 2018-12-31 | $1.22M 10-K · filed 2019-03-06 | |
| 2017-12-31 | $1.59M 10-K · filed 2019-03-06 | |
| 2016-12-31 | $1.85M 10-K · filed 2018-03-07 | |
| 2015-12-31 | $473.80K 10-K · filed 2017-03-08 | |
| 2014-12-31 | $57.12K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |